Pol Boudes

1.9k citations

58 papers · 768 indexed · h-index 16

Impact in

Nephrology top 5%
- Gout, Hyperuricemia, Uric Acid
Physiology top 10%
- Lysosomal Storage Disorders Research

Papers in ⓘ

Physiology 21
- Lysosomal Storage Disorders Research 17
Epidemiology 20
- Liver Disease Diagnosis and Treatment 9
- Trypanosoma species research and implications 7
- Pneumocystis jirovecii pneumonia detection and treatment 4

Co-authors: Kathy Nicholls (7 shared papers)David J. Lockhart (7 shared papers)Dominique P. Germain (5 shared papers)Sheela Sitaraman (9 shared papers)Charles A. McWherter (6 shared papers)Alexandra Steinberg (9 shared papers)Roberto Giugliani (4 shared papers)Robert L. Martin (3 shared papers)
Journals: Molecular Genetics and Metabolism (6 papers)Contemporary Clinical Trials (3 papers)Journal of Hepatology (3 papers)Neuromuscular Disorders (2 papers)Annals of the Rheumatic Diseases (2 papers)
Partner nations: United States France United Kingdom

In The Last Decade

Pol Boudes

55 papers receiving 737 citations

Peers

Countries citing papers authored by Pol Boudes

Since Specialization

Citations

This map shows the geographic impact of Pol Boudes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pol Boudes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pol Boudes more than expected).

Fields of papers citing papers by Pol Boudes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pol Boudes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pol Boudes. The network helps show where Pol Boudes may publish in the future.

Co-authors

The 25 scholars most cited alongside Pol Boudes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Pol Boudes Line = papers co-authored together Pol Boudes links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 58 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies Orphanet Journal of Rare Diseases ·Dominique P. Germain, Roberto Giugliani, Derralynn Hughes, Atul Mehta, Kathy Nicholls, Laura Barisoni, Charles J. Jennette, Alexander Bragat, Jeff Castelli, Sheela Sitaraman, David J. Lockhart, Pol Boudes	2012	77
2	A pharmacogenetic approach to identify mutant forms of α‐galactosidase a that respond to a pharmacological chaperone for Fabry disease Human Mutation ·Xiaoyang Wu, Evan Katz, Maria Cecilia Della Valle, Kirsten Mascioli, John J. Flanagan, Jeffrey P. Castelli, Raphael Schiffmann, Pol Boudes, David J. Lockhart, Kenneth J. Valenzano, Elfrida R. Benjamin	2011	65
3	A Randomized, Double‐Blind, Active‐ and Placebo‐Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout Arthritis & Rheumatology ·Jeffrey E. Poiley, Alexandra Steinberg, Yun‐Jung Choi, Charles S. Davis, Robert L. Martin, Charles A. McWherter, Pol Boudes, (unknown)	2016	61
4	A Phase 2 study of migalastat hydrochloride in females with Fabry disease: Selection of population, safety and pharmacodynamic effects Molecular Genetics and Metabolism ·Roberto Giugliani, Stephen Waldek, Dominique P. Germain, Kathy Nicholls, Daniel G. Bichet, Johanna K. Simosky, Alexander Bragat, J. Castelli, Benjamin Elias, Pol Boudes	2013	56
5	Drug Compliance in Therapeutic Trials Controlled Clinical Trials ·Pol Boudes	1998	55
6	Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase PLoS ONE ·David G. Warnock, Daniel G. Bichet, Myrl Holida, Özlem Göker-Alpan, Kathy Nicholls, Mark Thomas, François Eyskens, Suma P. Shankar, Mathews Adera, Sheela Sitaraman, Richie Khanna, John J. Flanagan, Brandon A. Wustman, Jay Barth, Carrolee Barlow, Kenneth J. Valenzano, David J. Lockhart, Pol Boudes, Franklin K. Johnson	2015	49
7	The challenges of new drugs benefits and risks analysis: Lessons from the ximelagatran FDA Cardiovascular Advisory Committee Contemporary Clinical Trials ·Pol Boudes	2006	35
8	Disseminated Mycobacterium bovis Infection From BCG Vaccination and HIV Infection JAMA ·Pol Boudes	1989	35
9	Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb3) in Fabry Transgenic Mice and in the Plasma of Fabry Patients PLoS ONE ·Brandy Young-Gqamana, Nastry Brignol, Hui‐Hwa Chang, Richie Khanna, Rebecca Soska, Maria Fuller, Sheela Sitaraman, Dominique P. Germain, Roberto Giugliani, Derralynn Hughes, Atul Mehta, Kathy Nicholls, Pol Boudes, David J. Lockhart, Kenneth J. Valenzano, Elfrida R. Benjamin	2013	35
10	The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout The Journal of Rheumatology ·Alexandra Steinberg, Bradley Vince, Yun‐Jung Choi, Robert L. Martin, Charles A. McWherter, Pol Boudes	2016	33
11	Pharmacokinetics and Safety of Migalastat HCl and Effects on Agalsidase Activity in Healthy Volunteers Clinical Pharmacology in Drug Development ·Franklin K. Johnson, Paul N. Mudd, Alexander Bragat, Mathews Adera, Pol Boudes	2013	27
12	Multifocal multinucleated giant cell myelitis in an AIDS patient Neuropathology and Applied Neurobiology ·Christian Gény, Romain K. Gherardi, Pol Boudes, François Lionnet, Pierre Césaro, Françoise Gray	1991	21
13	Purely granulomatous Wegener's granulomatosis: A new concept for an old disease Seminars in Arthritis and Rheumatism ·Pol Boudes	1990	21
14	Gene therapy as a new treatment option for inherited monogenic diseases European Journal of Internal Medicine ·Pol Boudes	2013	21
15	Risk Evaluation and Mitigation Strategies (REMSs): Are They Improving Drug Safety? A Critical Review of REMSs Requiring Elements to Assure Safe Use (ETASU) Drugs in R&D ·Pol Boudes	2017	17
16	A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. PubMed ·Stefano Vella, Adriano Lazzarin, Giampiero Carosi, Alessandro Sinicco, Orlando Armignacco, Gioacchino Angarano, Massimo Andreoni, Giuseppe Tambussi, Alessandro Chiodera, Marco Floridia, Sergio Scaccabarozzi, Karen Facey, I. B. R. Duncan, Pol Boudes, K. Bragman	1996	15
17	An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development Contemporary Clinical Trials ·Christopher Viereck, Pol Boudes	2011	14
18	Novel Quantitative Method to Evaluate Globotriaosylceramide Inclusions in Renal Peritubular Capillaries by Virtual Microscopy in Patients With Fabry Disease Archives of Pathology & Laboratory Medicine ·Laura Barisoni, J. Charles Jennette, Robert B. Colvin, Sheela Sitaraman, Alexander Bragat, Jeff Castelli, Dan B. Walker, Pol Boudes	2012	14
19	Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis Alimentary Pharmacology & Therapeutics ·Mazen Noureddin, Zachary Goodman, Dean Tai, Elaine Chng, Yayun Ren, Pol Boudes, Harold Shlevin, Guadalupe García‐Tsao, Stephen A. Harrison, Naga Chalasani	2023	13
20	An open‐label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function Clinical Pharmacology in Drug Development ·Franklin K. Johnson, Paul N. Mudd, Tara DiMino, Jennie Vosk, Sheela Sitaraman, Pol Boudes, Nicholas France, Carrolee Barlow	2014	10

About Pol Boudes

Pol Boudes is a scholar working on Physiology, Epidemiology, Rheumatology, Molecular Biology and Infectious Diseases, having authored 58 papers that have together received 768 indexed citations. Recurring topics across this work include Lysosomal Storage Disorders Research (17 papers), Liver Disease Diagnosis and Treatment (9 papers), Trypanosoma species research and implications (7 papers), Carbohydrate Chemistry and Synthesis (5 papers), HIV Research and Treatment (5 papers), Glycogen Storage Diseases and Myoclonus (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Pneumocystis jirovecii pneumonia detection and treatment (4 papers). The work is most often cited by research in Nephrology (105 citations), Physiology (347 citations), Virology (37 citations), Rheumatology (109 citations) and Epidemiology (246 citations). Pol Boudes has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Kathy Nicholls, David J. Lockhart, Dominique P. Germain, Sheela Sitaraman, Charles A. McWherter, Alexandra Steinberg, Roberto Giugliani, Robert L. Martin, Kenneth J. Valenzano and Franklin K. Johnson. Their work appears in journals such as Molecular Genetics and Metabolism, Contemporary Clinical Trials, Journal of Hepatology, Neuromuscular Disorders and Annals of the Rheumatic Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact